Application of brentuximab vedotin in Hodgkin lymphoma
10.3760/cma.j.cn115356-20200417-00097
- VernacularTitle:维布妥昔单抗在霍奇金淋巴瘤中的应用
- Author:
Ying YU
1
;
Lugui QIU
;
Shuhua YI
Author Information
1. 中国医学科学院血液病医院（中国医学科学院血液学研究所） 国家血液系统疾病临床医学研究中心 实验血液学国家重点实验室，天津 300020
- From:
Journal of Leukemia & Lymphoma
2020;29(9):519-524
- CountryChina
- Language:Chinese
-
Abstract:
Reed-Sternberg cells of Hodgkin lymphoma (HL) typically express CD30, while CD30 is rarely expressed in normal cells and can be rapidly internalized, making it an ideal target for monoclonal antibodies and antibody-drug conjugates. Brentuximab vedotin (BV) is a novel CD30-directed antibody-conjugated drug, and it is a landmark in HL treatment history. This article will describe the efficacy, tolerability and safety of BV as consolidation, salvage and combination therapy in HL.
